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Review Article
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Abstract: The population of people with a single-ventricle is continually increasing due to improvements
across the spectrum of medical care. Unfortunately, a proportion of these patients will develop heart failure.
Often, for these patients, mechanical circulatory support (MCS) represents the only available treatment
option. While single-ventricle patients currently represent a small proportion of the total number of patients
who receive MCS, as the single-ventricle patient population increases, this number will increase as well.
Outcomes for these complex single-ventricle patients who require MCS has begun to be evaluated. When
considering the entire population, survival to hospital discharge is 30–50%, though this must be considered
with the significant heterogeneity of the single-ventricle patient population. Patients with a single-ventricle
have unique anatomy, mechanisms of failure, indications for MCS and the type of support utilized. This has
made the interpretation and the generalizability of the limited available data difficult. It is likely that some
subsets will have a significantly worse prognosis and others a better one. Unfortunately, with these limited
data, indications of a favorable or poor outcome have not yet been elucidated. Though currently, a database
has been constructed to address this issue. While the outcomes for these complex patients is unclear, at least
in some situations, they are poor. However, significant advances may provide improvements going forward,
including new devices, computer simulations and 3D printed models. The most important factor, however,
will be the increased experience gained by the heart failure team to improve patient selection, timing, device
and configuration selection and operative approach.
Keywords: Mechanical circulatory support (MCS); ventricular assist device (VAD); single-ventricle; Norwood;
Glenn; Fontan; review
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Introduction
Individuals with single-ventricle physiology comprise a
complex, and heterogenous, sub-group of patients with
congenital heart disease (CHD). Palliation to singleventricle physiology involves multiple operations eventually
resulting in passive blood flow to the pulmonary circulation
with the single-ventricle providing systemic blood flow.

© Translational Pediatrics. All rights reserved.

When cardiac failure develops in these patients, providing
mechanical circulatory support (MCS) is an especially
challenging problem due to the altered systemic venous
return and arterial connections. However, MCS, in the
form of extracorporeal membrane oxygenation (ECMO) or
a ventricular assist device (VAD), may represent the only
alternative to death. While some initial studies have been
reported, the outcome of single-ventricle patients who
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require MCS remains unclear.
With improved operative techniques and critical care,
the single-ventricle population is continually increasing.
Currently, more than 1,000 new Fontan operations are
performed annually in the United States and Canada
alone (1). The first generation of surviving patients with
Fontan physiology are now well into adulthood (2).
These numbers include only patients who have reached
the Fontan stage, and do not include the single-ventricle
patients currently living at an earlier stage of palliation. As
the single-ventricle population has increased, heart failure
in patients with a single-ventricle has become the most
common indication for heart transplant in children (3).
Not surprisingly, in correlation, MCS for single-ventricle
patients has increased, and is only likely to further increase
in the future (4). Currently, nearly half of all pediatric
patients who are placed on ECMO for cardiac indications
have a single-ventricle (5).
ECMO has been utilized extensively in pediatric patients
due to its speed of initiation, ability to provide both cardiac
and pulmonary support, ability to support patients of any
size (except the smallest of neonates), and the ability to
seamlessly transition from cardiopulmonary bypass (CPB).
However, survival for patients who require ECMO is poor
for patients with CHD, and even worse for patients with a
single-ventricle (5). It is employed to allow for myocardial
recovery, support until a reparative operation can be
performed or (more recently) as a bridge to a VAD, and
potentially as a bridge to decision. ECMO, however, is
hampered by a significant complication rate that increases
with the duration of support (6,7). Currently, VADs have
been increasingly utilized in many pediatric situations (8-13).
A VAD offers the benefits of a longer duration of support,
therefore, allowing more time for either recovery or to
find a suitable donor (14). Therefore, ECMO and VAD
support should be treated as unique therapies with different
indications for use.
Importantly, while patients are often considered within
a single category, “single-ventricle”, they can develop
cardiac failure at any stage of palliation and at any time
postoperatively. Therefore, the term “single-ventricle”
encompasses a heterogenous patient population. Further,
the mode of failure is often distinct, within each stage of
palliation and for each patient specifically, making each
patient with cardiac failure and any form of single-ventricle
anatomy truly unique. Lastly, due to the small sample sizes,
ECMO and VADs are often considered together as MCS,
despite device selection having significant implications on
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the patient’s outcome.
This review focuses on the current utilization of MCS
in patients with a single-ventricle. As this is an uncommon
indication, and each situation is very unique, the data are
limited, as is the generalizability of the published literature.
We discuss the overall reported outcomes of MCS in
single-ventricle patients, the implications of the varied
cardiac anatomy, MCS device chosen, cannulation strategies
and technical considerations. Data from the largest existing
series is cited whenever possible. Case reports or small
series are used as necessary, though, with appropriate
consideration of a significant publication bias.
Outcomes
The current data available evaluating the survival of singleventricle patients who require MCS are quite limited and
difficult to interpret. Most consider the survival to hospital
discharge of single-ventricle patients who require MCS
to be 30–50% (4,15-18). When evaluating all patients
with a single-ventricle who underwent MCS over a
25-year period at a single institution, of 57 patients,
18 (33%) survived to hospital discharge (16). Considering
the Berlin Heart EXCORE IDE database, evaluating
outcomes for single-ventricle patients, survival of 26 patients
was 42% (4). Utilizing the KID (Kids Inpatient Database)
to analyze survival in single-ventricle patients who require
ECMO allowed for an analysis of 701 patients over 10 years;
overall survival was 43%, and importantly, the outcomes did
not improve over the decade evaluated (15). Though these
are the most informative studies available, each evaluated
the outcomes of a heterogenous patient population, with
unique anatomy and indications for MCS. Definitively, the
data does support that single-ventricle patients who require
ECMO are likely to have poor outcomes, even worse than
other CHDs (4). Additionally, patients who demonstrate
any type of end-organ dysfunction prior to MCS initiation
are more likely to have a poor outcome (9).
Impact of stage of palliation of single-ventricle physiology
Likely the most important factor impacting the anticipated
survival for any patient requiring MCS is the stage of
palliation (19). This is for many reasons, first, being
that the patient’s current anatomy likely impacts their
response to MCS (20). Additionally, stage of palliation
correlates with many factors that likely dictate the patient’s
outcome including: size, age, available devices, ability to
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Figure 1 Cannulation after stage I of palliation utilizing an arterial
Berlin Heart cannula as outflow placed within the common atrium
and the Berlin Heart aortic cannula using a Gore-Tex extension
into the neoaorta. The patient has a Blalock-Taussig shunt.

anticoagulate and availability of donors for transplant. In
addition, possibly the most important factor is indication.
Clearly a patient who requires ECMO for inability to wean
from CPB after Norwood is different than an adult with late
Fontan failure who requires VAD as a bridge to transplant.
First stage
Patients who require MCS after the first stage of palliation
are often suffering from post-cardiotomy shock. As
these patients recover from CPB and adapt to their new
circulation, MCS may be necessary as a bridge to recovery.
In these patients, the MCS must provide cardiopulmonary
support with ECMO or, if only cardiac support, provide
sufficient flow through the systemic circulation and the
systemic-pulmonary shunt. In the previously referenced
studies evaluating the survival for single-ventricle patients
who received MCS, survival of patients who required MCS
after their first stage were 32% for patients supported with
a VAD (16) and 11% when considering the Berlin Heart
EXCOR IDE database (4).
Most would expect this patient population to have a
poor survival, as it is essentially selected for neonatal postcardiotomy patients who are unable to tolerate their new
circulation. Indeed, the survival for these patients in the
reports referenced above is not good. Others, however,
have reported over 40% survival with MCS utilization after
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stage I of palliation (17). Substantially different results may
be in part due to device selection, surgical technique or
postoperative care, however, patient selection is by far the
most likely factor. Supporting this, when utilized on patients
who have a repairable problem (usually shunt thrombosis),
when MCS support is required between stages I and II,
survival greater than 80% is reported (18). Further, when
VAD implantation is utilized after every Norwood, even
in patients who are stable, survival approaches 90% (21).
Though some might state this as evidence for the
routine use of MCS after Norwood, much more likely, it
demonstrates the impact of patient selection. Whether
indiscriminate use of MCS would improve overall survival
by providing early assistance to the most difficult patients,
remains to be seen.
An additional consideration for post-Norwood patients
is the type of systemic-pulmonary shunt, Blalock-Taussig
(BT) or Sano. Though it has never been studied, the type
of systemic-pulmonary shunt will influence outcomes of
patients after stage I who require MCS. With a Sano shunt,
flow through the pulmonary circulation is dependent on
blood within the failing ventricle, which is diminished in
a ventricle that is decompressed. We have typically taken
down the Sano shunt and created a BT shunt at the time
of VAD implant; or, on occasion, we have disconnected the
proximal aspect of the Sano and reattached it to the outflow
graft of the VAD (Figure 1) (22).
Second stage
MCS after the second stage of palliation has the advantage
of a more efficient anatomy than a Norwood, due to the
superior cavopulmonary connection (SCPC) supplying
the pulmonary vasculature in series with the systemic
circulation (Figure 2). However, with only a SCPC, the
decompression of the single-ventricle has competing
implications. Both the VAD augmented cardiac output and
ventricular decompression act to increase flow through the
Glenn anastomosis and improve oxygenation. Conversely,
there will also be an increased flow of deoxygenated blood
through the inferior vena cava (IVC). The summation has
been shown in an experimental model to lead to increased
oxygen delivery (23). Additionally, in case reports, it leads
to improved hemodynamics (24,25). MCS use after the
second stage, when considering the previously discussed
manuscripts, has a survival of 36% for all VADs (16) and
58% when looking at the Berlin Heart EXCOR IDE
database (4). These are both very small patient populations,
11 and 26, respectively.
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Some institutions, feel that patients who deteriorate
shortly after Glenn are demonstrating their inability to
tolerate the circulation and that they warrant consideration
of SCPC takedown and recreation of the systemicpulmonary shunt while implanting the VAD (16). These
sentiments are based on poor outcomes with attempts
at VAD support immediately post SCPC. Importantly,

Figure 2 Cannulation after stage II of palliation. Similar
cannulas are utilized as after stage I. The superior cavopulmonary
anastomosis is demonstrated and the systemic-pulmonary shunt
has been taken down.

A

implantation of MCS on the systemic side would not
address underlying problems with pulmonary vasculature
or other limitations to pulmonary blood flow that are not
related to sufficient cardiac output. These patients would
subsequently require a heart transplant. As much as any, the
patients who require MCS after SCPC have outcomes that
remain unknown.
Third stage
For patients with a failing Fontan, when taken as a whole,
the previously referenced studies noted survival to hospital
discharge of 40% for any VAD (16) and 60% when
considering the Berlin Heart EXCOR IDE database (4).
Inflow cannulation can be performed via the ventricular
apex (Figure 3A) or the atrium (Figure 3B). The outcomes
for patients with a failed Fontan must be considered based
on indication for VAD implant. Certainly, those with
early Fontan failure are a different patient population than
those with late Fontan failure. Further, in patients with
late Fontan failure, the indication for VAD can be either
impaired ventricular function (IVF) or preserved ventricular
function (PVF) but with failing Fontan physiology.
Heart failure in the acute postoperative period after
Fontan has been successfully supported with MCS in
multiple instances. Some are for patients in the acute
postoperative Fontan period (26), others for Fontan patients
who required additional cardiac operations and developed

B

Figure 3 HeartWare HVAD placement in patients with a failing Fontan. (A) The HVAD inflow cannula is placed within the ventricular
apex with the outflow cannula into the neoaorta; (B) the HVAD inflow cannula is placed into the atrium with the outflow cannula into the
neoaorta.
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postcardiotomy shock (27,28). There have been reports of
successful bridge to recovery postoperatively, after even
long durations of VAD support (29).
For late failing Fontan, indications typically fall on
the spectrum between IVF and PVF. Considering VAD
implant for these two indications, it is unlikely they would
have similar outcomes with the same support. Patients
with IVF would be expected to benefit quickly from a VAD
implanted to support the systemic ventricle, but those with
a predominately failing physiology may take significantly
more time to recover. This is what was initially seen with
heart transplant for failing Fontan, the outcomes for
patients with IVF were initially superior (30). Though,
with improved preoperative care, operative techniques and
postoperative care, it has now been shown that survival after
heart transplant may now be equivalent (31,32). It has been
argued that a patient with IVF would do very well with a
single VAD supporting the systemic circulation, whereas
a patient with predominately PVF may require support of
both sides of the circulation, either with two VADs or a
total artificial heart (TAH). There is insufficient data at this
point to argue either against or for such approaches; further,
few patients present with discrete phenotypes of one or the
other, with significant overlap in most.
These patients who survive into adolescence or
adulthood but subsequently develop late Fontan failure
comprise a group that should be expected to have a high
rate of survival. Indeed, many reports exist demonstrating
survival to transplant for both PVF (33,34) and IVF (35).
Considering that the vast majority are case reports, a
substantial publication bias probably gives a false impression
of the success rate. Likely one of the main factors leading
to poor outcomes is the reluctance of the heart failure
team to pursue VAD implant, either due to unfamiliarity
of the anatomy or acknowledgement of the increased risk
associated with the procedure (14). So when MCS is finally
initiated, the patient is more debilitated than a traditional
patient who requires VAD implant. Importantly, late failing
Fontans are a group of patients which will only increase.
Though the operations for this patient population are quite
difficult, with appropriate patient selection and timing,
outcomes should be expected to be quite high.
Device type
Currently, many devices are available to support patients
with heart failure. The device chosen depends on many
factors including the indication [anticipated recovery or
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bridge to transplant (BTT)], pulmonary function, anatomy
and size. In addition, if utilized as a BTT, the anticipated
duration on the waiting-list is an important factor and,
therefore, additional factors must be considered such as
antibody status.
ECMO is the first established MCS. Being comprised
of both a pump and an oxygenator, it has long been utilized
to treat patients with cardiorespiratory failure. It remains
very useful for multiple indications, mainly for its ease
and speed in initiation/cannulation and termination/
decannulation. It can be initiated using the internal jugular
and carotid in young children or the femoral artery and
vein in larger children and adults, or centrally via median
sternotomy. Additionally, transition from CPB to ECMO is
quite easy. It does, however, have a significant risk profile,
with a serious risk of adverse events with any significant
duration. Due to these attributes it is ideally suited for
emergencies or support that is anticipated to be of short
duration (6,7). Limitations of ECMO stem in part from the
typical required approach: peripheral cannulation generally
limits flow rates (in contrast to central cannulation) due to
vessel size, increased surface exposure from long segments
of an intravascular cannula (and hence greater chance
for activation of clotting cascades as well as the need for
anticoagulation), and inherent limitations of mobility and
rehabilitation potential related to concerns with cannula
dislodgment. Otherwise ECMO circuitry can be quite
similar to those commonly used in the pediatric setting with
temporary devices (see below) with the added oxygenator.
Many pediatric VADs are simply ECMO without the
oxygenator, such as a CentriMag or PediMag [St. Jude
Medical Inc. (Thoratec), St. Paul, MN, USA]. Though still
hampered by many of the disadvantages of ECMO, most
feel they are far better tolerated with a lower risk of adverse
events with a longer duration. Patients who have undergone
an operation may require transition from CPB to a VAD
of this type for a short period of time to allow for recovery
from the stress of an operation as well as the adaptation
to new anatomy (21). Additionally, for patients who
initially came off bypass, but then developed progressively
worsening failure, VAD support may prove necessary in the
acute postoperative period, potentially urgently. ECMO or
an extracorporeal VAD is ideally suited for these indications.
For longer-term support, a different set of devices has
emerged as the choice whenever possible. These include
the Berlin Heart EXCOR (EXCOR) (Berlin Heart, GmbH,
Berlin, Germany), the HeartMate II (HMII) [St. Jude
Medical Inc. (Thoratec), St. Paul, MN, USA] and the
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HeartWare HVAD (HVAD) (HeartWare International,
Framingham, MA, USA). The EXCOR has shown
significant utility in pediatric patients in nearly all settings,
including patients with a single-ventricle (4,9,11,36-38).
The EXCOR is an extracorporeal pneumatically driven
pulsatile device with a large controller tower. The HM II
and the HVAD are much smaller intracorporeal continuousflow (CF) devices with easily transported battery packs.
These CF devices, while originally designed for adults,
have been used extensively in pediatrics (39,40). Their use
in patients with a single-ventricle remains quite limited,
though there are case reports (33-35). In pediatric patients,
practice has recently shifted to CF devices in patients
large enough to support one (41). The CF design allows
for a smaller device, which allows for improved patient
mobility and rehabilitation. Going forward, the majority
of devices placed in patients of sufficient size will be a CF
device.
While not as commonly utilized, some report excellent
experiences with the Syncardia Total Artificial Heart
(Syncardia Systems, Tucson, AZ, USA) in pediatric patients,
and its use has been described in a single-ventricle patient
(42,43). In a patient with a failing single-ventricle, most
specifically with failing physiology or a mixed picture, it
may prove to have significant utility. Theoretically, it could
allow for the advantages of BiVAD support with improved
rehabilitation due to the increased mobility over two
devices. Indeed, its use has been described successfully in a
patient with failing Fontan physiology (43).
We advocate for the use of an intracorporeal VAD
whenever possible, for multiple reasons including, the
demonstrated improved outcomes in other populations,
the improved ability for rehabilitation and the improved
quality of life (8,9,11,16,44). The Berlin Heart EXCOR
may be necessary if the patient is small, but if the patient
is large enough [body surface area (BSA) is >1 m2], a CF
VAD should be used. We prefer the HeartWare HVAD
due to its size. In the patient who is acutely postoperative,
either unable to wean from bypass or deteriorates in the
acute postoperative period, we recommend transition from
CPB to ECMO or VAD such as the PediMag (depending
on pulmonary function). If postoperative failure develops
suddenly and requires urgent MCS, ECMO should be
initiated peripherally. However, once it is determined
that there is no pulmonary pathology, the patient should
be converted to a VAD to allow for recovery or BTT.
Specifically, we attempt to avoid the use of an oxygenator
whenever possible (45).
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Configuration
When utilizing MCS in a patient with a single-ventricle, the
patient’s anatomy and pathology must both be considered
so that the MCS is used optimally. Patients with a singleventricle fail due to failure of the ventricle to support
the systemic circulation (or systemic and pulmonary in a
shunted patient), or due to their inability to tolerate their
passive pulmonary circulation. Therefore, the selection
of the device configuration is likely the most important
controllable factor, with the exception of whether or not
to utilize MCS at all. Multiple configurations are possible,
systemic VAD placement, VAD support for only the
pulmonary circulation and BiVAD or TAH support, all of
which have been described.
When supporting patients after stage 1 of palliation,
the device must provide flow to support both the systemic
and pulmonary circulation. We have recently come to
prefer a cannulation technique which utilizes the common
atrium for inflow and the neoaorta as outflow (22). In our
experience, we have found cannula selection to be very
important in limiting thrombus formation. For the inflow,
we prefer the arterial Berlin Heart cannula due to its smaller
surface within the atrium and lower likelihood of creating
stagnant flow. The outflow cannula is the Berlin Heart aortic
cannula with either a homograft or Gore-Tex (W.L. Gore
and Associates, Elkton, MD, USA) extension. If the patient
has a Sano shunt, this is taken down. To provide pulmonary
flow, either a BT shunt is created or the proximal end of
the Sano shunt is anastomosed end-to-side to the outflow
cannula via the homograft or Gore-Tex extension (45).
For patients after Fontan, the vast majority of patients
who receive VAD support, receive support of the systemic
ventricle. In a patient with IVF without other signs of
failure, this is the ideal treatment option. However, for
patients with failing physiology, or a more mixed picture,
the decision is more difficult. Our bias is that a single VAD
supporting the systemic ventricle will allow for improved
physiology as we believe all of these patients suffer from a
substantial, and under-appreciated, collateral burden that
“steals” 20–50% of cardiac output (and in turn an increased
volume load that burdens the single ventricle), in addition
to addressing any other underlying pulmonary circulation
issues, despite absence of hemodynamic significance
(i.e., if there is no gradient by angiography demonstrates
suboptimal anatomy). We do not believe that pulmonary
blood flow can be augmented by “sucking” it across the
pulmonary vascular bed. A decrease in central venous
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pressure upon initiation of inotropic support demonstrates
the potential benefit of a VAD for these patients. Some
have argued that support of both the systemic ventricle and
the right side may be superior, especially if the elevated
pulmonary pressures are thought unlikely to be “reversible”.
It is hard to believe that these same patients, not too long
ago, were deemed to have low enough pulmonary pressures
to undergo Fontan palliation. Nevertheless, it has been
shown that a single right sided VAD may be sufficient for
some patients (46). However, placement of a right sided
VAD may be technically quite challenging.
BiVAD support has been described in the failing Fontan
patient (47). Though some feel that the addition of a
second VAD increases the risk of complications, it has been
shown that BiVAD support can be done without increased
risk (9,11,48). Implantation of a second pump does,
however, increase the surgical complexity of an already
difficult operation. Further, the disadvantage of impaired
rehabilitation due to a second device may have significant
implications. Though, if necessary, not providing support
for the pulmonary circulation would leave the patient
debilitated, clearly a worse alternative.
Technical difficulties
Utilization of MCS in patients with a single-ventricle
is a surgical challenge. These patients require a redosternotomy, often times multiple, with what can be a
difficult dissection. Patients often have foreign material
present, either a Fontan conduit or a systemic-pulmonary
shunt. Injury to any native or foreign structures may have
catastrophic implications. Further, if a cardiac chamber is
inadvertently entered during dissection prior to cross-clamp
application, an air embolism is possible. In addition, these
patients commonly have substantial collateral flow, which
can complicate the dissection prior to CPB and impair
visualization once on bypass. Regardless of the configuration
of VAD support chosen, sternal entry and the dissection
process may be difficult in these patients. For that reason,
in our population of multiple redo-sternotomies a femoral
arterial and venous line are placed prior to incision. These
lines are large enough to accept a wire for percutaneous
CPB initiation if it becomes emergently necessary.
For patients who are going to have a VAD implanted,
inflow cannula placement is more complex than in a normal
ventricle. The inflow can be placed in either the apex of
the ventricle or the atrium. Placement within the apex is
more familiar to most surgeons but may require significant
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trabecular resection. Atrial placement avoids the difficulties
with trabeculations, but the inherent lack of strength in
the atrial wall does create concerns for suck down events.
Single-ventricle patients may have a single right ventricle,
which will undoubtedly have more-dense trabeculations
than a single left ventricle. Further, as the ventricle dilates,
the apex can be displaced, making it difficult to identify. As
the geometry of the single-ventricle dilates and changes,
the angle of the inflow cannula may be difficult to predict.
There have been multiple reports of VAD implants into
the systemic right ventricle of patients with dextrotransposition of the great arteries (D-TGA) after atrial
switch (49-51) or in congenitally corrected TGA (CC-TGA)
(52-54). In many, apical inflow cannula placement is aided
by use of a needle with transesophageal echocardiographic
guidance (55-57). This will allow the cannula to be far
enough from the septum and atrioventricular valve to
avoid suck down events. In pediatric patients, especially if
the ventricular muscle is thinned, the depth of the inflow
cannula can be decreased by placing multiple felt rings on
the epicardium (35). This latter approach has also been taken
with cannulation of the common atrium using the HVAD,
successfully bridging Fontan patients to transplant (58).
For patients who do require right sided support, usually,
significant surgical reconstruction is necessary; a capacitance
chamber may need to be constructed to accommodate the
inflow cannula. This chamber must be created from the
already surgically manipulated superior vena cava (SVC)
and IVC. Outflow cannula placement is into the pulmonary
arteries, which also require reconstruction. This significantly
increases the operative and bypass time and the surgical risk.
As an alternative to BiVAD support, a TAH can be utilized. In
this instance, the operative difficulty revolves around returning
the systemic venous return to the right atrium, which may
need reconstruction, again a major operation (43).
Future directions
ECMO utilization has been shown to be increasing as a
percentage of hospitalizations for patients with a singleventricle (4). In addition, the population of patients who
exist with a single-ventricle is continuing to increase.
Knowing that a certain percentage of these Fontan patients
will eventual fail means that, going forward, an increasing
number of VADs will be implanted in patients with a
single-ventricle. As many of these will be placed as a BTT,
improved timing and patient selection of VAD implantation
will become crucial. To accomplish this, risk factors for a
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poor outcome need to be more clearly delineated. To that
end, a registry was created to identify the risk factors and
evaluate the outcomes of patients with a single-ventricle
who require MCS (59).
For these complicated patients, going forward, computer
models have been developed (60). Using computer models,
a simulator has been created to allow for the simulation of
a surgical procedure to evaluate the impact of operations
at all three stages of palliation (61). These, and other,
computer models can be used demonstrate the impact of
MCS utilization in patients with different anatomy (20). As
the number of patients treated increases, these models could
potentially become more accurate and robust. Theoretically,
these could be used to simulate different devices placed
in different configurations. This could have a significant
impact on preoperative planning.
In patients with single-ventricle and other complex
CHDs, three-dimensional (3D) printing has been utilized
in some of the most difficult scenarios (62,63). It provides
the spatial orientation to potentially improve preoperative
planning. Further, it is a useful tool to aid communication
with the patient and family, cardiologists and critical care
team (64). It has shown utility in allowing for preoperative
planning of inflow cannula placement when faced with
the challenges of implanting a VAD into a systemic right
ventricle (65). Going forward, it may be utilized with more
frequency with these complex cases.
For Fontan patients, a unique device has been proposed,
and tested in an animal model, a viscous impeller pump
(VIP) (66). This device is inserted transvenous and is placed
at the junction of the SVC/IVC and PAs (67). As the device
rotates, the right sided pressure is augmented and cardiac
output is improved (68). It could be used in the failing
Fontan, specifically for patients with failing physiology.
This could provide temporary support to improve the endorgan function in a patient prior to transplant (69). Further,
it could improve patient selection by identifying those who
recover end-organ function, presumably a marker for a
good outcome post-heart transplant. Currently the use of
this device is preclinical.
There are new devices on the horizon in the adult
population that could be brought into the pediatric realm.
Recently the relatively new HeartMate 3 device [St. Jude
Medical Inc. (Thoratec)] has shown promise, with improved
6-month outcomes compared to the HM II, and has a size
more comparable to the HVAD (70). The HeartWare
MVAD is another device that initially showed promise,
especially with its very small size, however, it is not yet
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available. Finally, the PumpKIN trial continues testing of
the Jarvik 2015, a CF device which could support even the
smallest of patients (71).
Certainly, in all centers where MCS is utilized in patients
with a single-ventricle (either pediatric or adult), experts
in every field must be readily available. Others have noted
the benefits of a multidisciplinary approach consisting
of surgeons and heart failure specialists, intensivists,
hematologists, pharmacists, nurses and potentially
psychiatrists and infectious disease physicians (72). We feel
this is absolutely necessary to optimize the outcomes of
these very difficult patients.
Conclusions
Patients with a single-ventricle comprise a heterogenous
and inherently difficult patient population. When their
condition necessitates the initiation of MCS, currently, their
outcome is difficult to predict. Further studies are needed
evaluating unique cannulation strategies, outcomes based on
stage of palliation, patient selection and timing of MCS. A
registry has been created to aid in answering these questions
in the future (59).
The number of single-ventricle patients who require
MCS is going to increase as the overall single-ventricle
population increases. As patients with a failing singleventricle age and an inevitable portion develops heart
failure, some have dubbed a heart transplant the “fourth
stage” (73). Likely, many of these patients will be considered
at some point for possible VAD support. Though currently
the outcomes are poor, there is promise, that with improved
devices, increased experience and the development of risk
factors to improve patient selection and operative timing,
that outcomes will improve significantly.
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